Cite

HARVARD Citation

    Masuda, N. et al. (2022). Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort. European journal of cancer. pp. 108-118. [Online]. 
  
Back to record